Podcasts about ons

“Everyone will probably say this, but it is so true. Do not cram the night before the exam. The most important thing the night before the exam is to get a good night's sleep. You might be so nervous. You're like, ‘I can get any new information that matters right before the exam,' but you can't. Any information that you know you will have gotten in the time that you spent studying already. Really, you have to trust yourself,” Talia Lapidus, BSN, RN, professional staff nurse in the neonatal intensive care unit at UPMC in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about preparing for the NCLEX. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: Episode 85: Nursing Resilience and Self-Care Aren't Optional Episode 27: How Self-Care Can Impact Your Nursing Practice ONS Voice articles: OCN® Certification Test-Taking Tips to Ease Your Anxiety Find Your Balance Between Work, Life, and School Practice These Five Self-Care Strategies in Less Than Five Minutes ONCC Certification Exam Resources: Benefits of certification  Prepare to test Review courses Practice tests ONS books: BMTCN® Certification Review Manual (second edition) Breast Care Certification Review (second edition) Core Curriculum for Oncology Nursing (seventh edition) Study Guide for the Core Curriculum for Oncology Nursing (seventh edition) ONS course: OCN® Certification Review Bundle ONS Wellness Breaks Joint Position Statement From ONS and ONCC: Oncology Certification for Nurses ONS Nurse Well-Being Learning Library Oncology Nursing Foundation Resiliency Resources NCLEX (National Council of State Boards of Nursing's licensure exam) UWorld Quizlet Cleveland Clinic article: How Box Breathing Can Help You Destress To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The biggest studying tip that I found when I was studying was just consistency. I was studying every day, and I was setting time aside every single day to study. It's really just about making sure that it's part of your daily routine. At first it feels weird, like going from school to just straight up studying. But that's really what school was for—finding a study method that works for you, that you can then implement into studying for the biggest test that you have to take.” TS 1:52 “Practice questions are everything. You mentioned already that the NCLEX questions are formulated in a very specific way. And I know some schools do all their exams in NCLEX style, but some schools don't, so some people might not know how the NCLEX formulates their questions. A lot of the time it's like you have to pick the most correct out of a lot of correct answers. And if you don't have practice critically thinking about how to answer these questions, you might get tripped up. So practicing these questions, knowing what the test will be like, is so important.” TS 6:46 “Time management is the best thing that you can do. When I was working, I still had goals for myself for studying, even if it was just study this topic today or do 10 practice questions today. Anything that you're doing is better than nothing. So if you have to color-code your life and, in Google Calendar, have two hours to work, two hours to study, or eat lunch from 12 to 1, and then from 1 to 2, you study. Anything that you have to do to make sure that you get at least a little bit of studying in matters.” TS 9:05 “You don't have to be studying 24/7. You have a life outside of the exam, and you should still live it. You should still see your friends, and you should still go out to eat. Do things that make you feel good because if you are not in your best headspace, you won't be able to study appropriately.” TS 18:50

De laatste reguliere Pantelic Podcast van het seizoen! En dat betekent dat we met zijn vieren opnemen. Bart erbij op een online verbinding en Jan, Wessel en Kevin vertrouwd in de studio. En wat is er veel te bespreken... Het vertrek van Farioli, wie hem moet opvolgen, de rol van Kroes, de uitdagingen op de transfermarkt. Enzovoorts, enzovoorts... We blikken ook nog een keer terug op het seizoen, met hoogte- en dieptepunten. Bedankt voor het luisteren dit jaar! Er komen nog twee mooie specials met Jari Litmanen en Marko Pantelic aan en hopelijk zien we je op on evenement op 29 mei!(0:00) Intro(3:10) Opname met Jari Litmanen(5:20) Het vertrek van Farioli(42:05) Het Pantelic Plakboek(44:33) Istruzioni per Farioli(46:20) Wie moet Farioli opvolgen?(01:05:00) Pittige transferzomer op komst(01:19:50) Nog één keer terugblikken op het seizoen(01:31:07) Ons podcast-seizoenEen live-evenement om het seizoen samen af te sluiten!29 Mei organiseren we van 17:00 tot 23:00 een live-evenement bij Studio Wieman in Amsterdam Noord om samen met jullie het seizoen af te sluiten! Verwacht een live-podcast met Ajax-gasten, een quiz, live-entertainment en vooral heel veel gezelligheid. En misschien hebben we zelfs nog wat verrassingen in petto! Hopelijk tot dan!Tickets haal je hier: shop.ticketapp.com/xoyghtrkhj125 Jaar Ajax van Brian Borghardt bestellen?Dat kan via: https://www.kickuitgevers.nl/onze-boeken/sport/125-jaar-ajax/'Eenmalige Ajacieden' willen lezen?Bestel hem dan op: https://boekengilde.nl/boekenshop/eenmalige-ajacieden/?srsltid=AfmBOoprtZVdSRy5vaNGwUSgp1Oh3shzb7iNxw_uQ0c8rgY3lpGaH9mUHet boek van Mike van Damme en Jari Litmanen bestellen?Dat kan hier: https://www.sauberhaus.nl/boeken/zijn-legendarische-jaren-bij-ajaxZie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

VOLG ONS OP Substack ALS JE DEZE ZOMER NIET ZONDER EREDIVISIEPRIKKELS KAN!Welkom bij De Derde Helft, de Eredivisie door de ogen van een stelletje amateurs. Deze week zijn dat Tim, Snijboon en Gijs. Zij worden vergezeld door iemand die de uitslagen te horen kreeg door in te bellen in de show: ROGIER PABLO.Boodschap uit de business lounge:Beveilig je online leven met Surfshark VPN! Ga naar surfshark.com/dederdehelft of gebruik de code DEDERDEHELFT voor 4 extra maanden Surfshark. Geld-terug-garantie van 30 dagen inbegrepen.Volg ons op Instagram, YouTube, TikTok. Ons kanaal volgen op Spotify is ook goed voor de datahttps://www.instagram.com/dederdehelftpodcast/https://www.tiktok.com/@dederdehelftpodcast/Geproduceerd door: Tonny Media Hosted on Acast. See acast.com/privacy for more information.

Jezus doet veel met ons weinig

“A lot of other disease sites, they have some targeted therapies, they have some immunotherapies [IO]. In lung cancer, we have it all. We have chemo. We have IO. We have targeted therapies. We have bispecific T-cell engagers. We have orals, IVs. I think it's just so important now that, particularly for lung cancer, you have to be well versed on all of these,” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about lung cancer treatment. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 16, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to lung cancer treatments. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episode: Episode 359: Lung Cancer Screening, Early Detection, and Disparities ONS Voice articles: Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Cisplatin Oncology Drug Reference Sheet: Lazertinib Oncology Drug Reference Sheet: Nivolumab and Hyaluronidase-Nvhy Oncology Drug Reference Sheet: Fam-Trastuzumab Deruxtecan-Nxki Optimize Your Testing Strategy and Improve Patient Outcomes With NeoGenomics' Neo Comprehensive™–Solid Tumor Assay Clinical Journal of Oncology Nursing article: Oncogenic-Directed Therapy for Advanced Non-Small Cell Lung Cancer: Implications for the Advanced Practice Nurse ONS Biomarker Database ONS video: What is the role of the KRAS biomarker in NSCLC? Biomarker Testing in Non-Small Cell Lung Cancer Discussion Tool ONS Huddle Cards: Checkpoint inhibitors External beam radiation Monoclonal antibodies Proton therapy To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Unfortunately, because lung cancer is pretty aggressive, we'll see lung cancer mostly in stage IV. So about 50%–55% of all cases are not caught until they are already metastatic, or stage IV. And then about another 25%–30% of cases are caught in stage III, which means they're locally advanced and often not resectable, but we do still treat that with curative intent with concurrent chemoradiation. And then 10%–20% of cases are found in the early stage, and that's stage I and II, where we can do surgical approaches.” TS 2:53 “The majority of radiation that you're going to see is for patients with stage III disease that's inoperable. At my institution, a lot of stage III is inoperable. Now, neoadjuvant immunotherapy has changed that a little bit. But if you have several big, bulky, mediastinal lymph nodes that makes you stage III, surgery is probably not going to be a great option. So we give curative-intent chemoradiation to these patients.” TS 10:51 “Oligoprogression would mean they have metastases but only to one site. And sometimes we will be aggressive with that. Particularly, there's good data, if the only site of progression is in the brain, we can do stereotactic radiation to the brain and then treat the chest with concurrent chemoradiation as a more definitive approach. But outside of that, the majority of stage IV lung cancer is going to be treated with systemic therapy.” TS 15:00 “It's important for nurses to know that there's a lot of different options now for treatment. Probably one of the most important things is making sure patients are aware of what their biomarker status is, what their PD-L1 expression level is, and make sure those tests have been done. … It's good that the patients understand that there's a myriad of options. And a lot of that depends on what we know about their cancer, and then that guides our treatment.” TS 31:05

Albanië, Kosovo en Moldavië - alle drie de kleine landen zijn sterk afhankelijk van wat er in de wereld om hen heen gebeurt en voelen dat direct. Moldavië, met een oorlog in buurland Oekraïne, wacht met spanning af wat de Roemeense presidentsverkiezingen van zondag gaan brengen. Op de uitslag hebben de Moldaviërs zelf invloed. Ongeveer een miljoen Moldaviërs hebben een Roemeens paspoort, waaronder kiesgerechtigden. Voor Moldavië maakt het nogal wat uit wie er wint zondag, de pro-Europese Nicușor Dan of de radicaal-rechtse George ‘Roemenië eerst’ Simion. Floris zocht uit hoe de Moldaviërs naar deze verkiezingen kijken. Albanië dan, specifieker de premier Edi Rama, die zondag voor de vierde keer tot premier werd gekozen. De EU omarmt hem graag, want hij is pro-Europa. Maar die verkiezingen zelf, verliepen die wel zo netjes? De OVSE is kritisch. Standbeelden van Bill Clinton, Madeleine Albright, een boulevard genoemd naar George Bush, overal Amerikaanse vlaggen - Kosovo is niet alleen pro-EU, maar vooral pro-Amerika. In ieder geval voordat Donald Trump het voor de tweede keer tot Amerikaans president schopte. Zijn maatregel om ontwikkelingshulpagentschap USAID te ontmantelen laat zich voelen in Kosovo, ziet Geert Jan. Helaas geen mop, Joost had wat beters te doen. Wel wat extra's: Ons interview met Edi Rama. Vooruitblik op de Roemeense presidentsverkiezingen. De grote Albanese vier van de popmuziek. Hosts op locatie: Geert Jan Hahn Floris Akkerman See omnystudio.com/listener for privacy information.

Parlementslede is geskok oor die polisie se versuim om bewerings van intimidasie deur die InterCape en Golden Arrow-busdienste te ondersoek. 'n Beplande gesprek in Istanboel tussen Kijif en Moskou wankel. Ons kyk na die belangrikheid van tegnologie in die landbousektor.

Het einde van Handelingen betekent ook het einde van de verhalende delen van de Bijbel. Nu volgt een serie brieven geschreven door sommige van de hoofdfiguren uit het Nieuwe Testament: de apostelen Paulus, Petrus en Johannes, twee broers van Jezus (Jakobus en Judas) en een onbekende schrijver. Deze brieven zijn ontzettend belangrijk, want ze leggen ons uit wat het Goede Nieuws nu precies is. We horen rechtstreeks van mensen die Jezus op aarde hebben meegemaakt, die jarenlang het Oude Testament hebben bestudeerd en die specifieke openbaringen van Jezus hebben gehad. Dit zijn de mensen die door Jezus persoonlijk zijn geroepen om te vertellen wat Gods reddingsplan voor de wereld is. Zij hebben de eerste kerken gesticht en geleid. Maar de brieven zijn wel allemaal in een bepaalde context geschreven. Het is makkelijk om ze uit hun verband te rukken en helaas gebeurt dat ook vaak. Omdat in de volgende hoofdstukken elke brief kort wordt besproken, gaan we niet op alle details diep in. We richten ons op de hoofdlijnen en het grote verhaal van God en mens. Bij elke brief geef ik je voor zover mogelijk de achtergrond, zodat we de tekst en de boodschap beter begrijpen.   Romeinen (10 minuten) Na het Oude Testament zagen we eindelijk de beloofde Verlosser op het toneel verschijnen, maar… Hij ging ook weer terug naar de Hemel. Wel kwam de heilige Geest en die nam het werk over. De heilige Geest is actief in mensen en één van die mensen was Paulus. In Handelingen kwamen we Paulus tegen als de Jood die de volgelingen van Jezus gevangen probeerde te nemen en zelfs te doden als zij het goede nieuws probeerden te delen. Jezus greep Hem op een dag in zijn nekvel en ook Paulus werd een christen. Sterker nog, hij is één van de belangrijkste verspreiders van het geloof geworden. Dankzij de kerken die hij stichtte bereikte het evangelie de uithoeken van het Romeinse rijk. Paulus schreef ook veel brieven, waarvan sommige bewaard zijn gebleven. Eén van de bekendste en zeker één van de belangrijkste brieven, is de brief die hij aan de kerk in Rome richtte. Voordat we dieper op de brief ingaan, even een korte biografie van deze Paulus. Paulus is zijn Griekse naam. In het Hebreeuws heet hij Saul (of Saulus), net zoals de eerste koning van Israël. Hij werd omstreeks het jaar nul geboren en kwam uit de stad Tarsus, gelegen in het huidige Turkije. Hij was een Jood, maar ook een Romeins staatsburger. Hij moet een gedreven man zijn geweest, want hij was lid van de Farizeeën. Dat waren godsdienstige leiders die zich erg strikt aan de wetten van God hielden. Een groot deel van zijn leven woonde hij in Jeruzalem. Tot hij Jezus, na diens dood en opstanding, ontmoette op de weg naar Damascus. Hij kwam tot geloof en verbleef enkele jaren in wat nu Jordanië is. Tijdens die periode heeft hij veel openbaringen van God gekregen. Die theologische kennis heeft hij verwerkt in zijn brieven. Paulus en Rome Zoals we in Handelingen zagen, heeft Paulus minstens drie zendingsreizen gemaakt. Aan het eind van zijn derde reis ging Paulus naar Jeruzalem. Daar werd hij opgepakt door de Joden en uiteindelijk kwam hij in handen van de Romeinen. Na twee jaar in ‘voorlopige hechtenis' te hebben gezeten, deed Paulus een beroep op de keizer. Als Romeins burger had hij het recht om in Rome te worden berecht. Na een gevaarlijke reis, die zijn metgezellen en hij ternauwernood overleefden, kwam Paulus in Rome aan. Daar werd hij onder huisarrest geplaatst. In deze periode schreef hij een groot deel van zijn brieven. Niet de brief aan de Romeinen overigens. Die had hij voor zijn arrestatie al geschreven, waarschijnlijk in het jaar 56 vanuit Korinte. Uiteindelijk werd Paulus vrijgesproken en kon hij weer enige tijd buitenshuis evangeliseren. Hij kon niet lang van zijn vrijheid genieten. Paulus werd opnieuw opgepakt. Inmiddels was er een nieuwe keizer en was de vervolging toegenomen. Paulus werd in een cel gestopt en uiteindelijk onthoofd. Vermoedelijk ergens tussen 64 en 68 na Christus. In de tijd dat Paulus zijn brief aan de Romeinen schreef, bestond de kerk daar al enige tijd. Het zou zelfs kunnen dat de wortels van de Romeinse kerk helemaal teruggaan naar de dag waarop de apostelen de heilige Geest in zich kregen en ze op straat preekten tegen alle pelgrims. In het begin bestond de kerk in Rome dus vooral uit Joden, later kwamen daar ook andere nationaliteiten bij. Op een gegeven moment kwam er echter een keizer aan de macht die alle Joden verdreef uit Rome. Pas na vijf jaar mochten ze terugkomen. Al die tijd hadden de niet-Joden de kerk in Rome geleid en dus waren veel Joodse gebruiken verdwenen. Dat zorgde voor verdeeldheid, vooral tussen het Joodse en het niet-Joodse kamp. Paulus besloot Rome te bezoeken en kondigde zijn bezoek aan met deze brief. Hij hoopte twee dingen te bereiken: ten eerste dat er meer eenheid zou komen en ten tweede dat de christenen in Rome hem konden helpen een zendingsreis naar Spanje te maken. (Het is niet bekend of hij deze reis ooit heeft gemaakt.) De brief aan de Romeinen is lang en soms ingewikkeld. Zelfs de apostel Petrus geeft toe dat de brieven van Paulus af en toe moeilijk te begrijpen zijn, maar ze vertellen wel de waarheid (2 Petrus 3:16). Tegelijk is ‘Romeinen' misschien wel de beste uitleg van wat het goede nieuws precies is. Laten we maar eens naar deze brief gaan kijken. ‘Voor dit evangelie schaam ik mij niet' Direct aan het begin vat Paulus bovendien zijn hele boodschap samen, als hij zegt: Voor dit evangelie schaam ik mij niet, want het is Gods reddende kracht voor allen die geloven, voor Joden in de eerste plaats, maar ook voor andere volken. In het evangelie openbaart zich dat God enkel en alleen wie gelooft als rechtvaardige aanneemt, zoals ook geschreven staat: ‘De rechtvaardige zal leven door geloof.' - Romeinen 1:16-17 In de rest van dit Bijbelboek legt hij uit wat het evangelie inhoudt, hoe God de mensen redt die geloven, zowel de Joden als de niet-Joden, en dat wij dus alleen maar hoeven te geloven. Paulus toont aan dat de wereld van binnen verrot is door het werk van de zonde. Ons hart en ons verstand zijn niet zuiver meer. Van nature keren we ons af van God en omarmen we afgoden. We proberen ons geluk en onze betekenis te vinden in materiële dingen. We eren wat geschapen is en niet de Schepper. Als de Joden dit lezen, zouden ze naast hun schoenen kunnen gaan lopen. Zij zijn toch Gods uitverkoren volk? Maar zo werkt het niet, legt Paulus uit. Ook zij staan schuldig tegenover God, zoals blijkt uit de verhalen in het Oude Testament. Zij hebben Gods wetten en voorschriften gekregen, maar niemand kan zich daaraan houden. Het logische gevolg is dat ieder mens verloren zou moeten gaan. Gelukkig is er evangelie - goed nieuws! Paulus zegt: Gods gerechtigheid, waarvan de Wet en de Profeten al getuigen, wordt nu ook buiten de wet zichtbaar: God schenkt vrijspraak aan allen die in Jezus Christus geloven. En er is geen onderscheid. Iedereen heeft gezondigd en ontbeert de nabijheid van God; en iedereen wordt uit genade, die niets kost, door God als een rechtvaardige aangenomen omdat hij ons door Christus Jezus heeft verlost. - Romeinen 3:21-24 God ziet je zonden niet meer De wet laat zien wat goed is in Gods ogen, maar is niet in staat om ons te bevrijden van de zonde. God moet dus iets buiten de wet om doen. Dat heeft hij gedaan door Jezus in onze plaats te straffen. Iedereen heeft gezondigd, maar als je in Jezus gelooft, ziet God jouw zonden niet meer. Er is voor jouw overtredingen betaald en dus mag je bij Gods familie horen. Paulus noemt dit proces ‘rechtvaardiging'. Je wordt ‘rechtvaardig' gemaakt. Al je zonden uit het verleden en alle zonden die je in de toekomst nog zult begaan, zijn vergeven. Het enige wat nodig is, is dat je gelooft. Met andere woorden: dat je vertrouwt op God, zoals we eigenlijk door de hele Bijbel heen hebben gezien. Paulus beschrijft dat Abraham, die de wet niet had, op Gods beloften vertrouwde en dat hij zo ‘rechtvaardig werd'. Dit leidt natuurlijk wel tot een probleem. Als onze zonden zijn vergeven, maakt het dan nog uit dat we zondigen? Sterker nog, hoe meer we zondigen, hoe meer genade God uitstort. Dus misschien is het wel beter juist meer te zondigen. Dat in geen geval, zegt Paulus. Door ons geloof verbinden we ons met de dood en opstanding van Jezus. Hij is dood voor de zonde en wij ook. Hoewel we moeten accepteren dat we altijd blijven zondigen, moeten we toch proberen dat niet te doen. Als we de heilige Geest in ons laten werken, gaan we steeds meer op Jezus lijken en Jezus was vrij van zonde. Dit proces noemen we ‘heiliging'. Het woord ‘heilig' betekent ‘apart gezet voor God' en het staat los van ‘rechtvaardiging'. Wij kunnen niets bijdragen aan onze rechtvaardiging. Jezus heeft ons verlost en als we in Hem geloven, zijn we rechtvaardig. We zijn dus gered en horen bij Gods familie. Het is niet zo dat God ons pas accepteert als we ons gedrag aanpassen, als we de zonde verslagen hebben. Wij kunnen die zonde niet verslaan, dat heeft Jezus al gedaan. Als we eenmaal zijn opgenomen in die familie, dan willen we steeds meer op Jezus gaan lijken. We doen ons best en de heilige Geest stelt ons in staat om te breken met zondig gedrag. Tegelijk zullen we nooit honderd procent volmaakt zijn en God weet dat. Niets kan ons scheiden van Zijn liefde Dit leidt wel tot strijd in ons binnenste, maakt Paulus duidelijk in hoofdstuk 7. We weten dankzij d...

Ons bring hulde aan Cornal Hendricks – 'n legende op én van die veld af. Marcell Coetzee en Dawie Spies deel persoonlike herinneringe en staaltjies oor die man agter die nommer 14-trui.

Ons erfgoed vertelt ons wie we zijn. Maar hoe weerbaar is dat eigenlijk in tijden van crisis? Zijn we wel voorbereid op natuurrampen, oorlog of een cyberaanval? Onder andere daarom riep Unesco De Dag van het Weerbaar Erfgoed in leven en die dag is vandaag! te gast: Angela Dellebeke, Secretaris Generaal van Blue Shield Nederland en Jeffrey van der Hoeven, Head Digital Preservation department bij de KB, de nationale bibliotheek

President Donald Trump smee bande in die Midde-Ooste. Politieke partye reageer op die groep Afrikaners wat as vlugtelinge in die VSA verwelkom is. Ons skakel oor na NAMPO, waar Udo Carelse met Agri SA en TLU SA praat oor boere se talle uitdagings.

Beluister in deze nieuwe podcast van Voice Faith naar lesavond 8 van de Holy Spirit School. God heeft jou een Helper gezonden die relatie met jou wil bouwen. Leer Hem kennen, vertrouwen en groei in de vruchten en gaven van de Geest om met kracht Gods Koninkrijk te bouwen en sterk te staan in alles wat God voor je heeft.Heb je gebed nodig? Ons gebedsteam staat voor je klaar! ☎️De gebedslijn is iedere dinsdagavond tussen 19:30 en 21:00 uur geopend: BEL (085) 488 2323Kijk voor meer info over de gebedslijn: https://frontrunnersministries.nl/gebed/Kijk iedere week naar Voice of Faith LIVE om 20:00.

Het Australië se state (en selfs Suid-Afrika) die kerk verbied om vir mense te bid in die naam van seksuele heroriënteringsterapie? Het die staat die reg om in te meng in die kerk se reëls ter wille van die beskerming van individue?Ons bespreek die saak met Dewald en Hugo.

Hoe lossen we energie-uitdagingen in de bouw praktisch op? Geen theoretische discussies, maar concrete innovaties van de bouwbeursvloer. Drie experts delen hun oplossingen: van slimmere stroomnetten tot zonnepanelen in kleur én groene daken die alles combineren.Beluister voor:Hoe Staqx gemeentes helpt met data-analyse en secundaire netten (zodra iemand zegt "er is geen netaansluiting", heeft Ben een antwoord).Waarom Soluxa zonnepanelen maakt voor monumenten, snelwegen én hekwerken – en waarom "lelijk" geen excuus meer is.Hoe Solar Sedum groene daken en zonnepanelen combineert, zodat je niet meer hoeft te kiezen tussen biodiversiteit of energie.Highlights:"Gemeentes zitten vast door nettekorten, maar met data kun je slimmer herbestemmen." – Ben Verstraten"Onze panelen zijn niet blauw, maar donkergroen of terracotta. Plotseling wil iedereen ze." – Lourens van Dijk"Waarom een groen dak óf zonnepanelen? Ons systeem doet beide, zonder gedoe." – Job ZaalWaarom dit ertoe doet:De bouw moet sneller, duurzamer en slimmer. Deze aflevering laat zien hoe het nu al kan – zonder wachten op perfecte wetgeving.Wil je pitchen in Pepper? Stuur een mail naar sandra@impact033.nlHost & Productie: Jos Hummelen | Montage: Maik Prooi | Muziek: Rinze Voorberg | Podcastvoice: Maud VermeulenDeze aflevering wordt mogelijk gemaakt door Impact033,Economic Board Utrecht, Dotslash Utrecht en Earth Valley.

Kijk in deze nieuwe video van Voice Faith naar de zevende lesavond van de Holy Spirit School. God heeft jou een Helper gezonden die relatie met jou wil bouwen. Leer Hem kennen, vertrouwen en groei in de vruchten en gaven van de Geest om met kracht Gods Koninkrijk te bouwen en sterk te staan in alles wat God voor je heeft.Heb je gebed nodig? Ons gebedsteam staat voor je klaar! ☎️De gebedslijn is iedere dinsdagavond tussen 19:30 en 21:00 uur geopend: BEL (085) 488 2323Kijk voor meer info over de gebedslijn: https://frontrunnersministries.nl/gebed/Kijk iedere week naar Voice of Faith LIVE om 20:00.

Send us a textMatteus 6:25-27 “Daarom sê Ek vir julle: Moet julle nie bekommer oor julle lewe, oor wat julle moet eet of drink nie, of oor julle liggaam, oor wat julle moet aantrek nie. Is die lewe nie belangriker as kos en die liggaam as klere nie? Kyk na die wilde voëls: hulle saai nie en hulle oes nie en hulle maak nie in skure bymekaar nie; julle hemelse Vader sorg vir hulle. Is julle nie baie meer werd as hulle nie? Trouens, wie van julle kan deur hom te bekommer sy lewe met een enkele uur verleng?Een van die grootste oorsake van stres in vandag se samelewing, is persoonlike finansies: Stygende pryse; stygende huurgeld; stygende rente op lenings; duur gesondheidsorg. Hoe hou ek kop bo water? Dit veroorsaak vir ontsettend baie mense groot bekommernis.‘n Newsweek artikel het onlangs my oog gevang: "Finansiële onsekerheid veroorsaak 'n geestesgesondheidskrisis." Kom ek haal ‘n paar syfers uit hierdie Amerikaanse opname aan:88% van die respondente ervaar 'n mate van finansiële stres. 65% het gesê hul finansies is hul grootste bron van stres, en dit het 'n beduidende negatiewe impak op hulle geestesgesondheid. 41% het selfs gesê hul finansies het hul geestesgesondheid "vernietig", en 64% het gerapporteer dat hulle permanent "finansiële moegheid" ervaar - 'n gevoel van uitbranding of uitputting in die hantering van geldsake.As dit is hoe die mense in die rykste land ter wêreld voel, hoeveel hoop is daar vir die res van ons? En hoop is presies wat ons nodig het. Hoop, ware hoop ... want dit is die een ding wat ‘n mens se bekommernis kan onderdruk en die stres kan verlig wanneer jy hierdie verraderlike finansiële waters moet navigeer. Ons lees in:Matteus 6:25-27 Daarom sê Ek vir julle: Moet julle nie bekommer oor julle lewe, oor wat julle moet eet of drink nie, of oor julle liggaam, oor wat julle moet aantrek nie. Is die lewe nie belangriker as kos en die liggaam as klere nie? Kyk na die wilde voëls: hulle saai nie en hulle oes nie en hulle maak nie in skure bymekaar nie; julle hemelse Vader sorg vir hulle. Is julle nie baie meer werd as hulle nie? Trouens, wie van julle kan deur hom te bekommer sy lewe met een enkele uur verleng?En weet jy wat doen die stres aan ons? Dit laat net ons probleme groter lyk as wat hulle in werklikheid is.Vertrou op God. Hy sal jou ook hierdeur dra.Want dit is Sy Woord. Vars … vir jou … vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

“The signaling and that binding of the MET and the HGF help, in a downstream way, lead to cell proliferation, cell motility, survival, angiogenesis, and also invasion—so all of those key cancer hallmarks. And because of it being on an epithelial cell, it's a really good marker because it's found in many, many different types of cancers, so it makes it what we call kind of a nice actionable mutation,” ONS member Marianne Davies, DNP, ACNP, AOCNP®, FAAN, senior oncology nurse practitioner at Yale Comprehensive Cancer Center in New Haven, CT, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the MET inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 9, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to MET inhibitors. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Capmatinib Oncology Drug Reference Sheet: Tepotinib Predictive and Diagnostic Biomarkers: Identifying Variants Helps Providers Tailor Cancer Surveillance Plans and Treatment Selection ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) Telephone Triage for Oncology Nurses (third edition) ONS courses: Safe Handling Basics ONS Biomarker Database ONS Huddle Cards: Monoclonal Antibodies Targeted Therapy ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets IV Chemotherapy Education Sheets Drugs@FDA To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The MET receptor was actually identified back in 1984. And it was actually identified as an oncogene in osteosarcoma. And so basically what that MET receptor does—it's a tyrosine kinase pathway, and the ligand that it attaches to is something called HGF/SF. That's hepatocyte growth factor/scatter factor. And so this MET pathway tyrosine kinase pathway is really important in tumor cell growth and migration. And it's expressed specifically on epithelial cells, so that's going to really help us in identifying how it can be a pathway for cancer treatments.” TS 1:35 “But in the particular classes, there kind of are some unique things that are with these MET inhibitors. For example, crizotinib, we found early on, causes some vision changes. Patients would report things like floaters or a little bit of blurry vision. For the capmatinib, things like elevation of amylase and lipase, fluid retention and bloating, and hypersensitivity reactions and photosensitivity.” TS 7:36 “Other things to teach for the TKI is the self-management strategies in terms of nausea management and dietary changes for the risk of peripheral edema. Having them do things like maybe doing daily weights, or at least weights every other day, and sometimes doing limb measurements so it can help us really quantify the amount of fluid retention they have. And then from a nursing perspective, meeting with these patients, is to do really good skin inspection. When people have peripheral edema, they're at risk for skin breakdown, and that can lead obviously to infection.” TS 16:06 “The biggest [misconception] is that people assume that all MET mutations are going to be equally responsive to the same targeted therapies, that all of the abnormalities are the same and react the same, and they really don't. We're really diving down and carving that pie thinner and thinner in terms of each individual MET abnormality, in terms of what drugs responds it to and what that means for patient outcomes and prognosis.” TS 25:21

Van middagdutjes tot saaie wandelingen: vroeger dachten we "nooit van m'n leven" – nu is het pure luxe. Een chaotische, grappige trip down memory lane over dingen die ineens... héérlijk zijn geworden. En hoe wazig ook - blijf zeker luisteren tot het einde. We beloven een leerrijk inzicht. ✨ Word een Very Important Listeners van de show en krijg naast 2 podcastafleveringen ook een extra maandelijkse podcast: Vraag Maar Raak! Daarin beantwoorden we jouw persoonlijke vragen. Krijg ook toegang tot onze Discord-chat met gelijkgestemden. En alle extra podcasts van voorgaande jaren.

As summer heats up, deodorant becomes a faithful ally. But this product can be very dangerous. On May 2022 a 14 year old girl, Giorgia Green, died from inhaling deodorant. The teenager, who was on the autistic spectrum, liked to spray deodorant on her blankets as she found the smell comforting. "The smell of it gave her a certain sense of relaxation," said her father. Sadly her cause of death was found to be "unascertained but consistent with inhalation of aerosol” and although it is not common she is not alone. According to the Office for National Statistics, (ONS) "deodorant" was mentioned on 11 death certificates between 2001 and 2020. Though, it is likely that the actual number of deaths are higher than this, due to the fact that specific substances are not always mentioned on death certificates. What is dangerous in deodorant? Why are people not being made aware of the danger? Should we stop using aerosol deodorants? In under 3 minutes, we answer your questions! To listen to the last episodes, you can click here: ⁠What are earworms, the songs we just can't get out of our heads?⁠ ⁠Is it a good idea to sleep with my pet?⁠ ⁠Who are digital nomads, the new generation of remote workers?⁠ A Bababam Originals podcast, written and produced by Amber Minogue. First Broadcast: 23/2/2023 Learn more about your ad choices. Visit megaphone.fm/adchoices

Ons strafrechtsysteem, bijna iedereen heeft er wel een mening over: langer straffen, meer regels en hard optreden tegen schuldigen. Maar kan dat niet anders? In de documentaire 'Vergeven of Vergelden' worden strafrechtadvocaten Wikke Monster en Klaartje Freeke gevolgd in hun bijzondere, en vrij zeldzame aanpak. Ze willen de zachte krachten in het strafrecht een stem geven, maar hoe dan?  Te gast: Wikke Monster en Klaartje Freeke.

Kommer oor 'n ISIS-aanval in Mosambiek. Ons praat met 'n militêre ontleder. Stygende watervlakke hou gevaar in vir oeste in die Laer-Oranjerivier-streek in die Noord-Kaap. 'n ANC-faksie wil die miljardêr en sokkeradministrateur, Patrice Motsepe, se arm draai om as ANC-presidentskandidaat te staan.

LES 124Laat me mij herinneren dat ik één ben met God.Vandaag zullen wij opnieuw dank betuigen voor onze Identiteit in God. Ons thuis is veilig, bescherming is gewaarborgd bij al wat we doen, macht en kracht staan ons ter beschikking in al wat we ondernemen. We kunnen falen in niets. Al wat we aanraken, gaat stralen met een licht dat zegent en geneest. Eén met God en met het universum gaan we vol blijdschap onze weg, met de gedachte dat God Zelf ons overal vergezelt.Hoe heilig is onze denkgeest! En alles wat we zien weerspiegelt de heiligheid binnen de denkgeest die één is met God en met zichzelf. Hoe makkelijk verdwijnen vergissingen en maakt de dood voor eeuwigdurend leven plaats. Onze lichtende voetsporen wijzen de weg naar de waarheid, want God is onze Metgezel terwijl we een tijdje onze weg door de wereld gaan. En zij die ons zullen volgen, zullen de weg herkennen doordat het licht dat wij dragen achterblijft, en toch bij ons blijft terwijl we verdergaan.Wat wij ontvangen is onze eeuwige gave aan hen die na ons komen en aan hen die ons zijn voorgegaan of een tijd bij ons bleven. En God, die ons liefheeft met dezelfde liefde waarin wij werden geschapen, glimlacht ons toe en schenkt ons het geluk dat wij gaven.Vandaag zullen we niet twijfelen aan Zijn Liefde voor ons, noch Zijn bescherming en Zijn zorg in twijfel trekken. Tussen ons vertrouwen en ons gewaarzijn van Zijn Aanwezigheid kunnen geen zinloze bezorgdheden komen. Wij zijn vandaag één met Hem in herkenning en herinnering. Wij voelen Hem in ons hart. Onze denkgeest bevat Zijn Gedachten, onze ogen aanschouwen Zijn liefelijkheid in alles wat we zien. Vandaag zien wij alleen het liefdevolle en het beminnelijke.We zien het in verschijningsvormen van pijn, en pijn wijkt voor vrede. We zien het in de radelozen, in de treurenden en bedroefden, de eenzamen en bevreesden, die de rust en vrede van denkgeest hervinden waarin ze werden geschapen. En we zien het eveneens in de stervenden en de doden, en brengen hen weer tot leven. Dit alles zien we, want wij zagen het eerst in onszelf.Geen enkel wonder kan ooit worden ontzegd aan hen die weten dat ze één zijn met God. Geen enkele gedachte van hen ontbeert de kracht om elke vorm van lijden in wie ook te genezen, in vroeger tijden en toekomstige tijden, even makkelijk als in degenen die nu naast hen gaan. Hun gedachten zijn tijdloos en staan even los van afstand als van tijd.Wij verenigen ons in dit gewaarzijn wanneer we zeggen dat we één zijn met God. Want met deze woorden zeggen we eveneens dat we verlost en genezen zijn, en dat wij dus ook kunnen verlossen en genezen. Wij hebben aanvaard en nu willen we geven. Want wij willen de gaven behouden die onze Vader geschonken heeft. Vandaag willen wij onszelf als één met Hem ervaren, zodat de wereld onze erkenning van de werkelijkheid delen kan. In onze ervaring wordt de wereld bevrijd. Wanneer wij onze afscheiding van onze Vader ontkennen, wordt deze genezen, tegelijkertijd met onszelf.Vrede zij met jou vandaag. Stel je vrede veilig door je te oefenen in het bewustzijn dat jij één bent met je Schepper, zoals Hij één is met jou. Wijd vandaag een keer, wanneer jou dat het beste lijkt, een half uur aan de gedachte dat je één bent met God. Dit is onze eerste poging tot een langduriger oefenperiode, waarvoor we geen regels of speciale tekst geven om je meditatie te leiden. We vertrouwen erop dat Gods Stem zal spreken zoals Hij dat vandaag geschikt acht, in de zekerheid dat Hij niet zal falen. Blijf dit half uur bij Hem. Hij doet de rest.Als je gelooft dat er niets gebeurt, zul jij er niet minder baat bij hebben. Je bent er misschien niet klaar voor om de winst vandaag in ontvangst te nemen. Toch zal die ergens eenmaal tot jou komen, en jij zult haar beslist herkennen wanneer ze met zekerheid in je denkgeest daagt. Dit halfuur zal met goud zijn omlijst, en alle minuten zullen als diamanten zijn gezet rond de spiegel die deze oefening jou presenteert. En je zult er het gelaat van Christus in zien, als weerspiegeling van het jouwe.Misschien vandaag, misschien morgen, zul jij je eigen gedaanteverandering* zien in de spiegel die dit heilig halfuur jou voorhouden zal om jezelf gade te slaan. Wanneer je er klaar voor bent, zul jij die daar vinden, binnen je denkgeest, erop wachtend te worden gevonden. Dan zul jij je de gedachte herinneren waaraan je dit halfuur hebt gegeven, in het dankbare besef dat geen tijd ooit beter werd besteed.Misschien vandaag, misschien morgen, zul jij in deze spiegel kijken en begrijpen dat het zondeloze licht dat jij ziet jou toebehoort en de liefelijkheid waar je naar kijkt de jouwe is. Beschouw dit halfuur als jouw geschenk aan God, in de zekerheid dat wat Hij teruggeeft een gevoel van liefde zal zijn dat je niet begrijpen kunt, een vreugde te intens voor jou om te bevatten, een aanblik te heilig om door de ogen van het lichaam te worden gezien. En toch kun je er zeker van zijn dat op een dag, misschien vandaag, misschien morgen, jij zult begrijpen en bevatten en zien.Voeg nog meer juwelen toe aan de gouden lijst om de spiegel die jou vandaag wordt voorgehouden, door elk uur voor jezelf te herhalen:Laat me mij herinneren dat ik één ben met God, één met al mijn broeders en mijn Zelf, in eeuwigdurende heiligheid en vrede.

“We spent time today discussing all the ways that owners can have a positive impact on career growth, whether you're a bedside nurse or just in teaching, research, hospital leadership. More than career growth, I see ONS as kind of a barrier to burnout and a catalyst for professional self-care. I think that no matter what aspect of oncology care you're involved in, it is a difficult and complex specialty. And I think with that can come a lot of challenges and tough days, and ONS brings a sense of community to that and, specifically, a community that is pushing cancer care forward,” ONS member Amy Kaiser, MSN, CPNP-PC, told Nick Escobedo, DNP, RN, OCN®, NE-BC, member of the ONS 50th anniversary committee, during a conversation about the benefits of ONS membership. Escobedo spoke with Kaiser, who joined ONS as a student, and Susan Groenwald, PhD, RN, ANEF, FAAN, a charter ONS member, about how ONS membership and resources have helped them grow in their careers. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: 50th anniversary series Episode 331: DNP and PhD Collaboration Strategies to Help Advance Oncology Care Episode 327: Journey of a Student Nurse: Choosing Oncology Nursing and the Value of a Professional Home Episode 160: Build Innovative Staff Education Tools and Resources ONS Voice articles: Your ONS Membership Offers You Benefits in Other Organizations, Too Co-Creation Modernizes ONS Chapters to Meet Member Needs ONS book: Cancer Basics (third edition) ONS course: ONS Cancer Basics™ Clinical Journal of Oncology Nursing article: Professional Organization Membership: The Benefits of Increasing Nursing Participation ONS membership ONS chapters ONS Communities Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Groenwald: “ONS was groundbreaking in so many areas. The area that sticks out to me was, I was the board liaison to the standards committee. And so, the development of oncology nursing standards, it was a hallmark and critical to the field and to me and my practice, as well as education. It was very exciting time.” TS 4:18 Kaiser: “I think that my very first introduction to cancer care came from the Cancer Basics course. I think I feel fortunate that I probably was the recipient of a lot of the efforts of Susan, who has pioneered so many of these different oncology resources. I had the benefit of being at school during a time where there were a ton of resources available through ONS.” TS 5:38 Groenwald: “Having attended the meetings and getting involved in some of the committees is where I met people and worked with people. And that became, for me, very vital for doing a book, where it was a contributed book, an edited book [Cancer Nursing: Principles and Practice], so we had lots of different chapters and contributors, but I met them all through ONS. And how we communicated was via the old-fashioned mail and telephone. I didn't even have a computer. We typed the whole manuscript, thousands and thousands of pages, the first couple editions.” TS 12:25 Kaiser: “What's so wonderful about going to [Congress] is everybody there is looking to move oncology nursing forward and meet people and connect and network. And it's this, you know, magical space of people who are meeting and sharing shared experiences, and I got to feel all of that prior to even being an oncology nurse. And I went home from that first conference, immediately discussed with my manager that I wanted to move to the oncology floor, and I did. But it was meeting all of those people and hearing about those career paths that did that for me.” TS 16:42 Kaiser: “I think people who are involved with ONS, I found, are also very, very willing to mentor. I was very fortunate as I was speaking to these people, not even being an oncology nurse, that they were so welcoming and wanted to welcome me into the specialty and wanted to show me how to get involved. So I think it's just taking that very first step of talking to somebody or going to that local chapter meeting, and then the rest of it becomes a lot easier.” TS 19:29 Groenwald: “One thing Amy mentioned that I think is important is that new nurses have so many opportunities. I think it's scary to put forth an abstract to speak at the conference. It's scary, but it's such a great opportunity for anybody at any level in their career. If they have something of interest to share, it's such a great place. I feel like it launched my career in terms of being able to speak in front of people and think critically about things and put together some projects. This all came from my work with ONS.” TS 20:51

Voor speelronde 30 bestaat de basis uit drie topamateurs: Gijs, Snijboon, Tim!Boodschap uit de business lounge: "adidas wil met You Got This positiviteit in sport aanmoedigen.Door positief gedrag vanaf de zijlijn of tribune houden sporters plezier in wat zij doen en blijven zij gemotiveerd, dus geef dat complimentje en dat schouderklopje. Lees meer via https://www.adidas.nl/yougotthis"Volg ons op Instagram, YouTube, TikTok. Ons kanaal volgen op Spotify is ook goed voor de data.https://www.instagram.com/dederdehelftpodcast/https://www.tiktok.com/@dederdehelftpodcastGeproduceerd door: Tonny Media Hosted on Acast. See acast.com/privacy for more information.

No podcast ‘Notícia No Seu Tempo’, confira em áudio as principais notícias da edição impressa do jornal ‘O Estado de S.Paulo’ desta segunda-feira (28/04/2025): O governo Lula já nomeou 323 aliados para conselhos de estatais e de empresas privadas das quais a União é acionista, segundo levantamento feito por Gustavo Côrtes. Com os adicionais obtidos pela participação nas reuniões dos colegiados, realizadas em intervalos que variam conforme as normas de cada organização, os contracheques podem chegar a mais de R$ 80 mil por mês. A lista de beneficiados inclui ministros, secretários-executivos e chefes de gabinete de ministérios, assessores do Palácio do Planalto, servidores comissionados, dirigentes e ex-parlamentares do PT e até apadrinhados da base de apoio do governo no Congresso. Parte dos cargos foi distribuída a figuras sem credenciais técnicas, por favorecimento político e como forma de complementar salários. Procurado, o Planalto disse que as nomeações seguem a Lei das Estatais e passam por avaliação dos comitês de elegibilidade das empresas, que verificam a conformidade dos processos de indicação. E mais: Política: Aposentados enfrentam saga para ter de volta descontos, após operação da PF Economia: Limites da rede de energia travam avanço de projetos de R$ 128 bilhões Metrópole: 25% concluem ensino médio na rede privada sem o básico em Matemática Internacional: Sob a sombra de Trump, canadenses escolhem hoje novo primeiro-ministroSee omnystudio.com/listener for privacy information.

In 'n wêreld waar mense elke dag nader aan mekaar behoort te leef, voel dit soms asof ons verder en verder uitmekaar dryf…

“Everyone's brain is extremely heterogenic, so it's different. You can put five of us in a room; we can all have the same diagnosis of a [glioblastoma multiforme], but all of ours can be different. They're highly aggressive biologically. It's a small area in a hard shell. So trying to get through the blood–brain barrier is different. There's a lot of areas of hypoxia in the brain. There's a lot of pressure there. The microbiology is very different—it's a cold environment versus a hot environment—and then the pathways are just different,” Lori Cappello, MSN, APN-C, CCRP, research advanced practice nurse at the John Theurer Cancer Center of Hackensack Meridian Health in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about brain malignancies and caring for patients with them. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 25, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to brain malignancies and their diagnosis and treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 235: Self-Advocacy Skills for Patients Episode 166: Cognitive Behavioral Interventions Help Patients With a Spectrum of Cancer Symptoms ONS Voice articles: Glioblastoma Diagnosis, Treatment, Side Effect Management, and Survivorship Recommendations Blocking Fatty Acid Storage May Induce Glioblastoma Apoptosis Brain Tumor Navigator Role Bridges the Intersection of Cancer and Neuroscience Researchers Tie More Cancers, Mortality to NF1 Disorders Larotrectinib and Other Tumor-Agnostic Targeted Therapies Are Leading Cancer Care Into the Next Frontier McCain Announcement Sheds Light on Nurses' Role in Advance Care Planning ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) Clinical Journal of Oncology Nursing articles: Implementing a Standardized Educational Tool for Patients With Brain Tumors Undergoing Concurrent Temozolomide and Radiation Therapy Exercise Intervention: A Pilot Study to Assess the Feasibility and Impact on Cancer-Related Fatigue and Quality of Life Among Patients With High-Grade Glioma Society for Neuro-Oncology Musella Foundation End Brain Cancer Initiative Brain Tumor Network American Brain Tumor Association Glioblastoma Research Organization Brain Tumor Funders' Collaborative Optune Gio® website Nurse.org article: Mysterious Brain Tumor Cluster Grows: Another Nurse Diagnosed at Newton-Wellesley Lori Cappello's contact information: lori.cappello@hmhn.org To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “A glioblastoma actually is the most predominant brain tumor that we do see. It is the most diagnosed of the brain tumors. And then I would say that an anaplastic astrocytoma is probably the second diagnosed. Historically a GBM, they used to say was probably an elderly patient for these. But we are definitely seeing it diagnosed at a much younger age now, definitely much more prevalent for people under 60.” TS 3:17 “Nine times out of ten, either a patient out of nowhere has a seizure, or they present with what they think are stroke-like symptoms. They noticed that they were slurring, or they were becoming more forgetful, or a family member noticed it and said, ‘Hey, what is going on with you?' But usually they present to the [emergency department], and a [computed tomography] scan is always done first. And lo and behold, something is seen.” TS 4:50 “The only other U.S. Food and Drug Administration-approved treatment that has come along in the last 20 years is a device called Optune Gio, which is an alternating electric field that stops cell division at the mitosis stage.” TS 7:45 “They lose so much of their independence, especially if they don't have a caregiver or help. That is huge. Medication management at home, to making sure that they're taking the medication properly, that they are actually taking their medication. Transportation is another huge problem. Getting to and from appointments is a challenge. Those are big issues—real, day-to-day, simple issues that people don't think about.” TS 17:11 “I think that having a brain tumor is very unique in the fact that you really need a dedicated neuro-oncologist. And depending on where you live, there are not a lot in the area. I actually had a patient that was moving out west, and the closest dedicated neuro-oncologist was four hours from them. … if you're not seeing dedicated neuro oncologists, you might not be getting the best treatment for yourself. So I think that having the resources and helping patients find the best care or the best brain tumor society—and there's a bunch of really good brain tumor groups to help patients find the best resources out there. I think that's really, really important for patients to know or for families to know.” TS 19:17 “So trying to help patients, there are always going to be challenges, and there are always going to be ups and downs. But finding that one person that they can go to, that they trust, that they have a great relationship with, whether at the doctor's office or whatever, and being available to them makes such a difference in their journey. I think that that is the most important for anybody in the journey.” TS 22:08 “With brain, there are going to be expectations. They are going to lose functionality at some point—and preparing them for that thing or preparing them for things that can help themselves. Like sometimes I say, ‘Go to the dollar store, get coloring books,' if they have weakness in one hand. Little tricks of the trade that can help them. About treatment options, going through the side effects, preparing them for whatever they can be prepared for.” TS 22:39 “It is not one of the better cancers to have, but it doesn't immediately mean it's a death sentence, and we shouldn't treat them like they're dying. We shouldn't take away their ability to live just because they were diagnosed with it. We shouldn't take away hope.” TS 25:35 “I think there's not enough discussed about [brain malignancies] and the lack of resources for this. These patients need a lot more resources and are available. There's just not enough available for it.” TS 26:59

Zoals elke donderdag presenteren we je ook vandaag een verse editie van Gamekings Daily. De dagelijkse podcast & video waarin twee presentatoren de laatste ontwikkelingen in de wereld die videogames heet, doornemen en er een mening over uiten. Dat alles in pak-hem-beet 20 minuten tijd. Vandaag zit Daan in zijn eigen man cave klaar om met JJ een aantal topics te bespreken. Zo praten de twee over de nieuwe trailer van PlayStation exclusive Ghost of Yotei en de bijbehorende releasedatum en ze uiten hun frustratie over het feit dat een Blade Runner-game zou zijn gecanceld. Deze onderwerpen en meer zie en hoor je voorbijkomen in de GK Daily van donderdag 24 april 2025.Ghost of Yotei oogt grafisch bijzonder indrukwekkendGK Daily is er op de maandag, dinsdag, woensdag en donderdag. Op de vrijdag serveren we onze community EvdWL, de uitgebreide podcast over al het nieuws van de afgelopen week. In deze editie praten Daan en JJ over de nieuwe trailer van Ghost of Yotei. Hoeveel indruk maakte deze video op beide heren en zijn er nieuwe gegevens bekend geworden over het spel van developer Sucker Punch? Wat vinden ze verder van de releasedatum die ze hebben gekozen: 2 oktober? Ligt dat niet te dicht op de mogelijke release van GTA 6? Of past het juist prima? Je krijgt het antwoord in deze video.Ons is gewoon even een Blade Runner-game door de neus geboordHet  tweede onderwerp draait om developer Supermassive Games, die naar verluidt bezig zou zijn geweest met een Blade Runner-game. Dit spel, dat de pre-productie fase was ontstegen, lijkt nu gekilled. Waarom is dat en wat zijn we mogelijk mis gelopen? Daan en JJ geven er hun eerlijke mening over. Net als ze dat doen bij nieuws over de vermeende schaarste van de Switch 2 en de mod-scene die druk bezig is Oblivion Remastered.Timestamps:00:00:00 Gamekings Daily van 24 april00:00:16 Introductie00:08:59 Gruwelijk mooie Ghost of Yotei uit op 2 oktober00:18:01 Blade Runner game gecanceld

Hoe lang is het geleden dat je jezelf nog eens echt in de ogen hebt gekeken? Jouw blik vertelt zoveel. Vandaag hebben we het over de spark en waarom het zo belangrijk is om te volgen waar jouw licht van aan gaat. ✨ Word een Very Important Listeners van de show en krijg naast 2 podcastafleveringen ook een extra maandelijkse podcast: Vraag Maar Raak! Daarin beantwoorden we jouw persoonlijke vragen. Krijg ook toegang tot onze Discord-chat met gelijkgestemden. En alle extra podcasts van voorgaande jaren.

Episode 359: Lung Cancer Screening, Early Detection, and Disparities “I was actually speaking to a primary care audience back a few weeks ago, and we were talking about lung cancer screening. And they said, ‘Our patients, they don't want to do it.' And I said, ‘Do you remind them that lung cancer is curable?' Because everybody thinks it is a death sentence. But when you're talking about screening a patient, I think it's really important to say, ‘Listen, if we find this early, stage I or stage II, our chances of curing this and it never coming back again is upwards of 60% to 70%,'” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about lung cancer screening. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 18, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to lung cancer screening. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 313: Cancer Symptom Management Basics: Other Pulmonary Complications Episode 295: Cancer Symptom Management Basics: Pulmonary Embolism, Pneumonitis, and Pleural Effusion Episode 247: Tobacco Treatment for Patients With Cancer ONS Voice articles: Lung Cancer Screening and Early Detection Drastically Improves Survival Rates Pack-Year History Is a Biased and Inadequate Criterion for Lung Cancer Screening Eligibility, Researchers Say CMS Expands Eligibility Criteria for Lung Cancer Screening With Low-Dose Computed Tomography Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Clinical Journal of Oncology Nursing articles: Nurse-Led Tobacco Cessation for Veterans Using Motivational Interviewing in a Lung Cancer Screening Program Identifying Primary Care Patients at High Risk for Lung Cancer: A Quality Improvement Study Oncology Nursing Forum article: Patient–Provider Discussion About Lung Cancer Screening Is Related to Smoking Quit Attempts in Smokers ONS Tobacco, E-Cigarettes, and Vaping Learning Library American Cancer Society Lung Cancer Screening Guidelines American Lung Association lung cancer resources To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Unfortunately, the current state of lung cancer screening is pretty low. Our rate of uptake in eligible patients is somewhere between 6% and 20%. And that falls much further below what we see for screening, such as breast cancer screening, prostate cancer screening, and colorectal cancer screening. So certainly, we can do better.” TS 1:32 “If you quit more than 15 or 20 years, your risk of developing lung cancer at that point is significantly lower. And so that's why once patients have quit more than 15 years, they're actually not eligible for screening anymore—because their risk of developing lung cancer is dramatically reduced. And that takes into account when you are a primary care provider, pulmonary, whatever field you work in, and you are running a screening clinic each year that you screen the patient, you have to remind yourself when they quit smoking, because once they reach that 15 years, then they're no longer eligible for screening.” TS 5:17 “One of the strategies that they've used to get the word out is, I watch a lot of baseball. I love the Philadelphia Phillies, watch Phillies games. And so at least once a year, maybe even twice a year, they will take an inning of the baseball broadcast on TV and on the radio separately, and they will bring on either an oncologist or pulmonologist from one of the local cancer centers in our area, and the whole inning—between batters of course—they will talk about lung cancer screening and why it's beneficial.” TS 13:16 “Medicare always has its idiosyncrasies. So Medicare—I went over the rules with you, so the age, the smoking. They follow all of it, except they have a slight difference in age. They cover it for age 50 to 77, as opposed to 80.” TS 16:52 “I think just the other thing that people don't think about is that to go get a medical test done, no matter what test it is, typically people have to take time off of work. And it can be really hard to do that when you are relying on your job, maybe you don't have vacation time, maybe you have children at home that you need to get home to. When people are weighing the risk/benefit and thinking, ‘Well, I'd love to get screened for lung cancer, but I just can't find time to fit it into my schedule, and my job won't let me take off.' These are all things that we don't always think about if you have the luxury of just taking the day off.” TS 20:01

The ONS, whose data is used by the government to help make decisions affecting millions of people in the UK, is under review following criticisms about its data. Fliss and James are joined by Professor of Economics at King's College London, Jonathan Portes who is also chair of the ONS Labour Market Stakeholder Advisory Panel. They also speak to Aled Maclean-Jones a former special advisor to the UK Treasury about the implications faulty data has on policy making decisions.

[NL volgt ENG] ‘Our country has been robbed, deposed, raped and looted by countries near and far, both friend and foe. This is Liberation Day.' With these words, president Trump announced the import tariffs he imposed on almost the entire world. What does Trump want to achieve with this trade war, and is it realistic that he will succeed? What will the consequences be for European citizens? Learn from political scientist Gerry van der Kamp-Alons and political economist Frank Bohn about Trump's trade war. Trump's Trade War | Current Affairs Lecture with political scientist Gerry van der Kamp-Alons and political economist Frank Bohn | Thursday 10 April 2025 | 12.30 - 13.15 hrs | Lecture Hall Complex, Radboud University | Radboud Reflects and VOX Read the review: https://www.ru.nl/en/services/sport-culture-and-recreation/radboud-reflects/news/trumps-trade-war-current-affairs-lecture-with-political-scientist-gerry-van-der-kamp-alons-and-political-economist-frank-bohn Never want to miss a podcast again? Subscribe to this channel! Also don't forget to like this podcast. Radboud Reflects organizes public lectures and courses about current affairs. Check our website for upcoming in-depth lectures: www.ru.nl/en/services/sport-cu…boud-reflects/agenda Do you want to stay up to date about our activities? Please sign in for the English newsletter: www.ru.nl//rr/newsletter -- ‘Ons land is beroofd, afgezet, verkracht en geplunderd door landen dichtbij en ver weg, zowel vriend als vijand. Dit is Bevrijdingsdag.' Met deze woorden kondigde president Trump de importtarieven aan die hij oplegde aan bijna de hele wereld. Wat wil Trump bereiken met deze handelsoorlog en is het realistisch dat hij daarin zal slagen? Wat zullen de gevolgen zijn voor Europese burgers? Leer van politicoloog Gerry van der Kamp-Alons en econoom Frank Bohn over Trumps handelsoorlog. Trump's Trade War | Actualiteitencollege met politicoloog Gerry van der Kamp-Alons en politiek econoom Frank Bohn | Donderdag 10 april 2025 | 12.30 - 13.15 uur | Collegezalencomplex, Radboud Universiteit | Radboud Reflects and VOX Lees het verslag: https://www.ru.nl/services/sport-cultuur-en-ontspanning/radboud-reflects/nieuws/trumps-trade-war-actualiteitencollege-met-politicoloog-gerry-van-der-kamp-alons-en-politiek-econoom-frank-bohn Like deze podcast, abonneer op dit kanaal en mis niks. Bekijk ook de agenda voor nog meer verdiepende lezingen: www.ru.nl/radboud-reflects/agenda Wil je geen enkele verdiepende lezing missen? Schrijf je dan in voor de nieuwsbrief: www.ru.nl/radboud-reflects/ser…ief-radboud-reflects

Het paasweekend staat weer voor de deur en dat betekent dat de Future Cup er ook weer aan komt! Geen beter moment om de trainer van Ajax onder-17 Paul Nuijten te gast te hebben in de Pantelic Podcast! Samen met Jan, Kevin en Wessel bespreekt hij zijn carrièrepad, waarin hij al vroeg bij Queen's Park samenwerkte met Marijn Beuker die hem begin dit seizoen naar Ajax haalde. Over het seizoen van "zijn" O-17, zijn voetbalvisie en de jeugdopleiding van Ajax. En natuurlijk over de aankomende Future Cup. Een mooi gesprek!(0:00) Intro en terugblik Willem II(4:15) Ons live-evenement!(5:28) Carrière tot nu toe(15:42) Dit O17-team(31:10) Training en visie(38:15) Het Pantelic Plakboek(41:12) De Future Cup(53:20) Breder voetbalperspectief(58:32) Plannen en ambities voor de toekomst(01:03:28) Ajax O19 wint topper van PSV(01:06:10) Ajax 1 uit tegen FC UtrechtWe gaan iets leuks doen!Een live-evenement om het seizoen samen af te sluiten!29 Mei organiseren we van 17:00 tot 23:00 een live-evenement bij Studio Wieman in Amsterdam Noord om samen met jullie het seizoen af te sluiten! Verwacht een live-podcast met Ajax-gasten, een quiz, live-entertainment en vooral heel veel gezelligheid. En misschien hebben we zelfs nog wat verrassingen in petto! Hopelijk tot dan!Tickets haal je hier: shop.ticketapp.com/xoyghtrkhjZie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

In 2025, workplace inclusion remains a key issue for the UK labour market. In summer 2024, the ONS reported the highest number of economically inactive people since 2012. While this label includes students and the retired, it more worryingly includes those who are unable to access the labour market due to either ill health or accessibility issues. As the working population across the Global North declines, access to employment opportunity is a social and economic issue. But too many modern workplaces are too slow redesign their hiring and employment processes to maximise inclusivity. In this episode, Dom, Jen and Cat chat with Ryan Curtis-Johnson from the Valuable500. He explains why inclusion is such a critical issue, not least when neurodivergence is on the rise. This conversation explores the opportunity for internal communication to create work cultures that boost diversity for enhanced organisational resilience.   Takeaways Inclusion is essential for a better society. The Valuable 500 aims to end disability exclusion. Businesses must navigate the fear of discussing disability. What's good for business is good for society. Inclusion should be embedded in all business practices. Neurodivergent individuals can bring unique strengths to the workplace. Organisations need to be flexible and inclusive in their policies. Diversity in problem-solving leads to better outcomes. Internal communication plays a crucial role in promoting inclusion. Sharing resources and knowledge fosters collaboration in inclusion efforts. Sharing best practices fosters inclusivity and learning. Disability should be embraced, not feared. Inclusion must be inherent in organisational behavior. Internal communicators play a vital role in promoting accessibility. Training on accessibility is essential for all employees. Care in communication can address societal challenges. Celebrating diversity can change negative perceptions. All employees should be allies for inclusivity. Inclusivity is a long journey that requires commitment. +++++ Find Ryan on LinkedIn: https://www.linkedin.com/in/ryan-curtis-johnson-b2233330/ The Valuable 500: https://www.thevaluable500.com/

Voor speelronde 29 bestaat de basis uit drie amateurs: Gijs, Tim en Pepijn. Boodschap uit de business lounge: "adidas wil met You Got This positiviteit in sport aanmoedigen.Door positief gedrag vanaf de zijlijn of tribune houden sporters plezier in wat zij doen en blijven zij gemotiveerd, dus geef dat complimentje en dat schouderklopje. Lees meer via https://www.adidas.nl/yougotthis"Volg ons op Instagram, YouTube, TikTok. Ons kanaal volgen op Spotify is ook goed voor de data.https://www.instagram.com/dederdehelftpodcast/https://www.tiktok.com/@dederdehelftpodcastGeproduceerd door: Tonny Media Hosted on Acast. See acast.com/privacy for more information.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for March 31-April 6, 2025: Cedars-Sinai Study Finds AI Tool Could Improve Care in Virtual Urgent Care Settings A Cedars-Sinai study suggests AI tools may enhance guideline adherence and decision-making quality in virtual urgent care, though clinician oversight remains essential. FDA Accepts Biologics License Application for ONS-5010 for Wet AMD The FDA has accepted a resubmitted BLA for ONS-5010, a proposed ophthalmic formulation of bevacizumab for wet AMD, advancing it toward potential approval. Socioeconomic Status Impacts Pediatric Preemptive Kidney Transplant Rates, Study Finds A retrospective study linked lower socioeconomic status to reduced access to preemptive kidney transplants in pediatric patients, underscoring ongoing disparities in care. FDA Clears Dexcom G7 15 Day CGM System The FDA has cleared the Dexcom G7 CGM system for 15-day use in adults, offering extended wear and continued improvements in diabetes monitoring technology. Icotrokinra Clears Skin Among 75% of Adolescents with Plaque Psoriasis New phase 3 data show once-daily icotrokinra improves skin clearance and maintains a favorable safety profile in adolescents with moderate-to-severe plaque psoriasis.

Finally, some good news for your Friday: the economy is growing! Just when everyone seems to be revising down expectations of growth, the Office for National Statistics (ONS) estimates that GDP grew by 0.5 per cent in February. It also revised January's figures upwards to give growth for the last quarter of 0.6 per cent, and annual growth of 1.4 per cent. It looks – for now – that the Reeves recession has been put on hold and that Labour's growth agenda could be working. That said, Labour cannot afford to celebrate just yet. There is reason to believe the figures could be overstated, and there are some trust issues with the ONS – the government last week announced a review of its ‘performance and culture'. These figures also do not take into account the tumult caused by Trump's tariffs. So what can we read into them? Will Trump undo Labour's progress? Lucy Dunn speaks to Michael Simmons and Katy Balls. Produced by Oscar Edmondson.

“It's been known for quite a while that [KRAS] is a mutation that leads to cancer development, but for really over four decades, researchers couldn't figure out a way to target it. And so, it was often considered something that was undruggable. But all of this changed recently. So about four years ago, in 2021, we had the approval of the first KRAS inhibitor. So it's specifically a KRAS G12C inhibitor known as sotorasib,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the KRAS inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 11, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to KRAS inhibitors used for cancer treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Cancer Symptom Management Basics series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: First KRAS-Targeted Therapy Receives FDA Approval for Lung Cancer Oncology Drug Reference Sheet: Adagrasib Oncology Drug Reference Sheet: Sotorasib ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS course: Safe Handling Basics ONS video: What is the role of the KRAS biomarker in NSCLC? ONS Targeted Therapy Huddle Card ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets Lumakras® (sotorasib) manufacturer website Krazati® (adagrasib) manufacturer website UpToDate Lexidrug (formerly Lexicomp) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “If we look at specifically non-small cell lung cancer, this KRAS mutation is one of the most frequently detected cancer drivers or driver mutations. It's thought that about a quarter of cases of non-small cell lung cancer have this KRAS mutation, and it's usually a specific amino acid substitution that we see in non-small cell lung cancer, so what's known as KRAS G12C mutation.” TS 2:31 “Both of these agents, sotorasib and adagrasib, have the same mechanism of action. They bind to a pocket, very specifically on the KRAS G12C protein, and they lock it in an inactive state so that it can't cause that downstream uncontrolled signaling to happen. So they're kind of shutting down the signaling, and therefore you don't get that uncontrolled cell growth and proliferation.” TS 4:27 “Another big difference to point out, and one that is often used in clinical practice to differentiate when to use these agents, is specifically adagrasib is known to have activity in patients with metastatic non-small cell lung cancer that have active brain metastases. In the clinical trial, they included patients with active brain metastases, and they found that this drug has great [central nervous system] penetration. And so it may be considered the agent of choice in patients with brain metastases.” TS 7:19 “Other considerations—I think one of the big ones—is that there are a lot of drug interactions. Just specifically calling one out that I think is pretty impactful, is sotorasib has an interaction with acid-suppressing medications. So there is the recommendation to avoid [proton pump inhibitors] and H2 antagonists in patients receiving sotorasib. They can take antacids, but you would need to space those out from their dose of sotorasib.” TS 14:14 “This needs to be a collaborative endeavor to make sure these patients are monitored appropriately. We are putting a lot of responsibility on the patients with all of this. So, again, completely administered generally in the home setting, a lot of monitoring, a lot of adverse effects, need for reporting and management—so there's a lot happening here. And it takes a team to accomplish this and to do it right. And I firmly believe that this is often a collaborative effort between our pharmacy and oncology nursing teams to make this happen. Working together to ensure outreach to patients—I think that patients are often more successful with these medications with early identification of toxicities when we're doing scheduled outreach.” TS 19:44

Eva kreeg een AHA-erlebniss in therapie. in deze aflevering hebben we het over belonging vs. becoming en hoe het moment waarop je voelt dat je nergens echt thuishoort, misschien wel het begin is van thuiskomen bij jezelf. Link naar het boek waar we het over hebben: https://shorturl.at/4gtOD ✨ Word een Very Important Listeners van de show en krijg naast 2 podcastafleveringen ook een extra maandelijkse podcast: Vraag Maar Raak! Daarin beantwoorden we jouw persoonlijke vragen. Krijg ook toegang tot onze Discord-chat met gelijkgestemden. En alle extra podcasts van voorgaande jaren.

Voor speelronde 28 bestaat de basis uit drie amateurs: Gijs, Tim en Pepijn. Pepijn wil doorbreken, Bas Nijhuis doet aan sfeerbeheer en Clarence Seedorf moet de geschiedenisboeken uit. Niet bang zijn, we hebben alle wedstrijden geduid.00:00 - INTRO04:37 - AJANAC13:02 - GROPSV18:32 - AZFEY26:10 - BUITENSPEL30:30 - GAEUTR34:55 - TWEFOR38:51 - HEEWIL41:48 - RKCHER44:07 - SPANEC46:33 - ALMPEC48:43 - EINDSPELBoodschap uit de business lounge: "Volg ons op Instagram, YouTube, TikTok. Ons kanaal volgen op Spotify is ook goed voor de data."Geproduceerd door: Tonny Media Hosted on Acast. See acast.com/privacy for more information.

“There have been many changes since the '70s that have shaped the nurse's role in administering chemo, and in supporting patients. The major change early on was the transition from that of nurses mixing chemo to that of pharmacists. Regulatory agencies like NIOSH and OSHA defined chemotherapy as hazardous drugs, and professional organizations became involved, leading to the publication of the joint ASCO and ONS Standards of Safe Handling,” ONS member Scarlott Mueller, MPH, RN, FAAN, secretary of the American Cancer Society Cancer Action Network Board and member of the Oncology Nursing Foundation Capital Campaign Cabinet, told Darcy Burbage, DNP, RN, AOCN®, CBCN®, ONS member and chair of the ONS 50th Anniversary Committee during a conversation about the evolution of chemotherapy treatment. Along with Mueller, Burbage spoke with John Hillson, DNP, NP, Mary Anderson, BSN, RN, OCN®, and Kathleen Shannon-Dorcy, PhD, RN, FAAN, about the changes in radiation, oral chemotherapy, and cellular therapy treatments they have witnessed during their careers. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: 50th anniversary series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 59: Blood and Marrow Transplant Nursing Episode 16: Navigating the Challenges of Oral Chemotherapy ONS Voice article:Safe Handling—We've Come a Long Way, Baby! ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (second edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: ONS Hematopoietic Stem Cell Transplantation™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ ONS/ONCC® Radiation Therapy Certificate™ Safe Handling Basics Oral Anticancer Medication Toolkit Oral Anticancer Medication Care Compass Patient education guides created as a collaboration between ONS, HOPA, NCODA, and the Association of Community Cancer Centers: IV Cancer Treatment Education Sheets Oral Chemotherapy Education Sheets Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Hillson: “I remember as a new grad, from back in '98, walking up to the oncology floor. We had patients with pink labels on the chart and that was the radiation oncology service. I hadn't heard of such a thing before. … I'd gone through nursing school and hospital orientation and unit orientation without ever hearing of these therapies. At the time, both the management and the union had no interest in specialist nurses, and the really weren't any books that were targeting the role. And it was very isolating and frightening. I was very glad to find ONS when I moved to the U.S. Right now, the Oncology Nursing Society Manual for Radiation Oncology, Nursing Practice, and Education, it's in its fifth edition and a sixth is underway. There's nothing else like it. Most books are very much geared towards other professions.” TS 5:34 Mueller: “We mixed our chemo in a very small medication room on the unit, under a horizontal laminar flow hood, which we later discovered should have been a vertical laminar flow hood. Initially, we did not use any personal protective equipment. I remember mixing drugs like bleomycin and getting a little spray that from the vial onto my face. And to this day, I still have a few facial blemishes from that.” TS 14:28 Anderson: “As the increasing number of these actionable mutations continue to grow, so will the number of oral anticancer medications that patients are going to be taking. And we are already seeing that there's multiple combination regimens and complex schedules that the patients have to take. So this role the oral oncolytic nurse and the nursing role, like you said, it cannot be owned by one individual or discipline. So it's not a pharmacist; the pharmacies aren't owning this. The nurses are not owning this. It takes a village.” TS 32:12 Shannon-Dorcy: Then as immunotherapy comes into the picture, we start to learn about [cytokine release syndrome]. All of a sudden, we had no concept that this was a deadly consequence. ONS was on the front lines, convening people across the country together so we could speak to the investigative work with science and find ways that we could intervene, how we can look for signs of it early on with handwriting testing.” TS 39:58

Morse code transcription: vvv vvv Lucy Letby barrister to submit fresh evidence to review body Val Kilmer, Top Gun and Batman actor, dies aged 65 Private school parents must pay fair share, court told Tesla sales unexpectedly plunge after Elon Musk backlash Trump tariffs list The US global tariffs plan at a glance UK firms react to Trump tariffs Its a huge blow to Scotlands whisky industry Trump tariffs Worst offenders around world face import taxes up to 50 Man charged with 64 offences in Hull Legacy funeral home inquiry Women to continue having babies later in life, ONS projects How could they affect the UK and your money

Ons nieuws wordt gedomineerd door berichten over herbewapening, defensiebudgetten en de herinvoering van de dienstplicht. Wat lezen we? Een zorgvuldig gecreëerd vijandbeeld of de mening van de journalist? Welk beeld wordt er van onze vijand geschetst in tijden van internationale spanningen? En welke parallellen kunnen we trekken met de Koude Oorlog? Jort Kelder vraagt het prof. dr. Floribert Baudet, bijzonder hoogleraar Militaire geschiedenis (UvA).  Documentaire Andere Tijden over het vijandbeeld: https://anderetijden.nl/aflevering/875/Koude-Oorlog-Vijandbeeld (https://anderetijden.nl/aflevering/875/Koude-Oorlog-Vijandbeeld) NOS artikel strijdmachten vergelijking: https://nos.nl/artikel/2561513-schaduwoorlog-in-volle-gang-maar-russische-invasie-van-navo-land-onwaarschijnlijk (https://nos.nl/artikel/2561513-schaduwoorlog-in-volle-gang-maar-russische-invasie-van-navo-land-onwaarschijnlijk)

Morse code transcription: vvv vvv Trump tariffs list The US global tariffs plan at a glance Man charged with 64 offences in Hull Legacy funeral home inquiry UK firms react to Trump tariffs Its a huge blow to Scotlands whisky industry Women to continue having babies later in life, ONS projects Trump tariffs Worst offenders around world face import taxes up to 50 Val Kilmer, Top Gun and Batman actor, dies aged 65 How could they affect the UK and your money Private school parents must pay fair share, court told Tesla sales unexpectedly plunge after Elon Musk backlash Lucy Letby barrister to submit fresh evidence to review body

Morse code transcription: vvv vvv Private school parents must pay fair share, court told Man charged with 64 offences in Hull Legacy funeral home inquiry How could they affect the UK and your money Val Kilmer, Top Gun and Batman actor, dies aged 65 Trump tariffs list The US global tariffs plan at a glance Women to continue having babies later in life, ONS projects UK firms react to Trump tariffs Its a huge blow to Scotlands whisky industry Trump tariffs Worst offenders around world face import taxes up to 50 Lucy Letby barrister to submit fresh evidence to review body Tesla sales unexpectedly plunge after Elon Musk backlash

In this episode, we explore the profound impact of Kelli Anspach MSN, CV-BC, NPD-BC, CHPN®'s thriving and sustainable training program, which has successfully trained more than 1,000 hospital nurses over the past 10 years through the End-of-Life Nursing Education Consortium (ELNEC) program, founded by Betty Ferrell PhD, MSN, CHPN®. By providing nurses with the essential skills and knowledge to lead compassionate palliative care conversations, this initiative empowers staff to facilitate critical "goals of care" discussions with patients and families. In this episode, Kelli and Brett discuss how this training not only enhances collaboration with palliative care teams but also drives improved patient satisfaction and better overall care outcomes. Additionally, the conversation takes a closer look at the return on investment (ROI) for hospitals and demonstrates how training nurses across all service lines is a cost-effective strategy to elevate patient care, boost nurse confidence, and foster a more supportive health care environment. With the right education, staff can empower frontline nurses across various serious illness service lines to make a lasting, positive impact on patient care. HPNA is proud to partner with Betty Ferrell and City of Hope to offer virtual ELNEC Train-the-Trainer courses twice per year. Visit the HPNA website for more information on upcoming courses and to learn how you can make a difference at the system level in your own health care organization.     Kelli Maher Anspach, MSN, CV-BC, NPD-BC, CHPN® Kelli has her BSN and MSN from Drexel University. She holds multiple certifications: Cardiac Vascular Certified Nurse, Nursing Professional Development Specialist, Certified Hospice and Palliative Nurse. Kelli has her ONS chemotherapy administration certification, is a certified Aromatherapy provider, and a Level 2 Reiki practitioner. Kelli has planned, presented, hosted, and facilitated many conferences from Women and Heart Disease to Nursing Research to Integrative Therapies but the most rewarding was her work with End of Life Nursing Education Consortium (ELNEC). Kelli implemented ELNEC across a five-hospital health system from 2013-2018.  This included securing grant money for the project and educating more than 900 staff in end-of-life patient care. Kelli was the Winner of International ELNEC Award for excellence in education, has as presented at local and national conferences, and is published in her field.  Kelli continues to be a strong advocate for palliative care and started a palliative care champion model for nurses in her health system to support identified knowledge and practice gaps. Kelli is a Nurse Residency Facilitator where she helps to support and mentor new graduate nurses in their transition to their first year as a professional nurse and lectures for the program on End-of-Life Nursing and Self Care. She teaches classes in oncology, telemetry nursing, and preceptor development for her health system. Kelli is a mother of three, loves to dance and hike, and enjoys her day-to-day role as a Clinical Nurse Educator at Lankenau Medical Center, part of Main Line Health System.   Brett Snodgrass, DNP, FNP-C, ACHPN®, FAANP Dr. Brett Snodgrass has been a registered nurse for 28 years and a Family Nurse Practitioner for 18 years, practicing in multiple settings, including family practice, urgent care, emergency departments, administration, chronic pain and palliative medicine. She is currently the Operations Director for Palliative Medicine at Baptist Health Systems in Memphis, TN. She is board certified with the American Academy of Nurse Practitioners. She is also a Fellow of the American Association of Nurse Practitioners and an Advanced Certified Hospice and Palliative Nurse. She completed a Doctorate of Nursing Practice at the University of Alabama – Huntsville. She is a nationally recognized nurse practitioner speaker and teacher. Brett is a chronic pain expert, working for more than 20 years with chronic pain and palliative patients in a variety of settings. She is honored to be the HPNA 2025 podcast host. She is married with two daughters, two son in laws, one grandson, and now an empty nest cat. She and her family are actively involved in their church and she is an avid reader.

Voor speelronde 27 bestaat de basis uit drie amateurs (Gijs, Tim en Snijboon) en een échte professional: Almere City-legend Tim Receveur. Amateur Tim weet het nu zeker: Farioli is een betere trainer dan Bosz. Professional Tim geeft alle Almere-fans weer moed en Snijboon brengt een ode aan Danny Buijs. Niet bang zijn, we hebben alle wedstrijden geduid.00:00 - INTRO06:56 - PSVAJA18:16 - UTRHEE23:04 - FEYGAE28:18 - BUITENSPEL32:19 - HERTWE34:51 - NECAZ39:20 - NACGRO41:46 - FORSPA44:59 - PECRKC47:11 - WILALM52:00 - EINDSPELBoodschap uit de business lounge: "Volg ons op Instagram, YouTube, TikTok. Ons kanaal volgen op Spotify is ook goed voor de data."Geproduceerd door: Tonny Media Hosted on Acast. See acast.com/privacy for more information.

“And so you have different kinds of hazards with the drugs that you're using. That means that in the past, when a lot of oncology drugs, antineoplastic drugs used to treat cancer would have been added, you may see that a lot of oncology drugs either weren't added or they're added in a different place on the list than they were in the past. That's due to some of the restructuring of the list we'll probably talk about later,” Jerald L. Ovesen, PhD, pharmacologist at the National Institute for Occupational Safety and Health (NIOSH) and Centers for Disease Control and Prevention, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the latest update to the NIOSH list of hazardous drugs.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Episode Notes   NCPD contact hours are not available for this episode.  ONS Podcast™ episodes: Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs  Episode 142: The How-To of Home Infusions Episode 68: Empowering Healthcare Workers to Handle Hazardous Drugs Episode 53: Home Care Nursing for Patients With Cancer ONS Voice articles: Hazardous Drug Surface Contamination Prevails, Despite More Diligent PPE  NIOSH Releases Its 2024 List of Hazardous Drugs  No Place Like It: Home Care for Patients With Cancer  What Is ONS's Stance on Handling Chemotherapy While Pregnant, Breastfeeding, or Trying to Conceive?  What You Wear Matters When It Comes to Safety  ONS book: Safe Handling of Hazardous Drugs (Fourth Edition)  ONS course: Safe Handling Basics  Clinical Journal of Oncology Nursing article: Safe Management of Chemotherapy in the Home  ONS Learning Library: Safe Handling of Hazardous Drugs  ONS Position Statement: Ensuring Healthcare Worker Safety When Handling Hazardous Drugs  National Institute for Occupational Safety and Health article: Managing Hazardous Drug Exposures: Information for Healthcare Settings  NIOSH List of Hazardous Drugs in Healthcare Settings, 2024  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode  “So we look for a carcinogenic hazard. So does this molecule, does this chemical, this drug, have the ability to increase the risk of cancer? A lot of the time that will also tie with genotoxic hazards, but not always. There are some drugs on the list that are carcinogenic through other mechanisms. Sometimes carcinogenicity can be related to hormone signals, can lead to increased risk of cancer. There's some nuance there, but is it a carcinogenic hazard? That can get it onto the list. Is it a developmental and reproductive hazard?” TS 10:48  “NIOSH can't say what's right for every situation, but some organizations have suggested further precautions such as temporary alternative duty for workers who are pregnant or are looking to become pregnant. NIOSH can't say what's best for any given facility, but other organizations have given some good suggestions you may want to look into.” TS 13:18  “The list doesn't really rank hazard. I know a lot of people have kind of treated it that way a lot of times. We don't say that something is less hazardous if it's only a developmental or reproductive hazard, because if you're trying to have a child, then that's an important hazard to you. And we don't necessarily say something that's carcinogenic is more hazardous.” TS 14:34  “Some standard setting organizations have set standards for handling. Really in the oncology setting, particularly oncology pharmacy setting, it's really changed how some of the handling happens there because some of the standards come out of the pharmacy world. And what's happened there is some drugs that are oncology drugs, they might have been on table one before just because they were used in the treatment of cancer. They were antineoplastics, so they were on table one. Now, because they're not identified as a potential carcinogen and they don't have manufactured special handling information, they are now on table two.” TS 23:39  “Occasionally, if a drug comes out and has manufacturer special handling information, we'll go ahead and add it to the list. And since we won't add it into the publication, we typically have a table on that page that puts that there. If a drug is reevaluated and we find that the hazard is not as bad as expected or it's not a hazard, actually, and we can remove it from the list; sometimes we get new information and that happens.” TS 30:30 

“I genuinely think nurses and pharmacists need to know why these medicines are called hedgehog inhibitors so that we can, in fact, effectively educate our patients. Just because to date, this class has the weirdest name I've encountered, and I almost expect at this point that my patients are going to ask me about it. I think that we need to be informed that, just on, where do these names come from, why is it called this, and does it matter to my patient?” Andrew Ruplin, PharmD, clinical oncology pharmacist at Fred Hutchinson Cancer Center in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about hedgehog pathway inhibitors.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 14, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learners will report an increase in knowledge related to hedgehog pathway inhibitors used for cancer treatment.  Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ Pharmacology 101 series  ONS Voice articles: An Oncology Nurse's Guide to Targeted Therapy FDA Approves Glasdegib for AML in Adults Aged 75 or Older or Who Have Comorbidities Oncology Drug Reference Sheet: Glasdegib Understanding Precision Medicine Therapeutics ONS courses: Genomic Foundations for Precision Oncology ONS Cancer Biology™   ONS Guidelines™ and Symptom Interventions:  Diarrhea Fatigue ONS Huddle Card: Targeted Therapy ONS Learning Libraries: Oral Anticancer Medication Pain Management  Oral Chemotherapy Education Sheets American Association for Cancer Research article: Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia American Journal of Clinical Dermatology article: Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies Cureas article: Hedgehog Pathway Inhibitors: Clinical Implications and Resistance in the Treatment of Basal Cell Carcinoma International Journal of Molecular Sciences article: Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode  “Many patients unfortunately will have side effects with this class. I mean—and I know that's not controversial—but you actually find callouts in some of the kind of the national consensus guidelines. These treatments might not be tolerable for a decent number of patients. Some of these side effects can certainly reduce quality of life. Again, nothing that controversial here when we say it out loud, but just the frequency with which it occurs can make it quite difficult for some patients.” TS 9:13  “Certainly, based on what we said before, I think one of the easiest things to do for patients starting this class is to just make sure that they have really classical supportive medicines like antidiarrheals and antiemetics before they start treatment. Diarrhea, nausea occurred in about 20%–40% of patients across trials. So certainly patients should be aware of that risk. Again, not a controversial side effect, but it's just simple things we can do to make sure that our patients are quick to start treatment is to make sure that they have these medicines and they're educated on how to use them.” TS 11:21  “I think patients need to be aware that side effects, as I had mentioned before, can be especially frequent with this class. So for a patient, they need to be aware that communicating your needs to your oncology team is really crucial to their own ability to use these treatments with minimal interruptions.” TS 14:45  “I think that regardless of whoever is following up with our patients, though, as our arsenal of oral anticancer therapies does continue to expand, both nurses and pharmacists need to have specialized knowledge of these agents to be successful in their patient care roles.” TS 18:28  “When there are clear recommendations for reproductive health, as I summarized before with these agents, I obviously think we need to be aware of them and not just defer to these generic recommendations. Because if you just defer to, ‘Well, use barrier contraception and then for a week after your last dose,' you know, ‘Okay, it's not true with these agents.'” TS 24:37   

“You can give someone a survivorship care plan, but just giving them doesn't mean that it's going to happen. Maybe there's no information about family history. Or maybe there's information and there's quite a bit of family history, but there's nothing that says, ‘Oh, they were ever had genetic testing,' or ‘Oh, they were ever referred.' So the intent is so good because it's to really take that time out when they're through with active treatment and, you know, try to help give the patient some guidance as to what to expect down the line,” Suzanne Mahon, DNS, RN, AOCN®, AGN-BC, FAAN, professor emeritus at Saint Louis University in Missouri, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about breast cancer survivorship.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 14, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learners will report an increase in knowledge related to breast cancer survivorship.  Episode Notes   Complete this evaluation for free NCPD.   Previous ONS Podcast™ site-specific episodes: Episode 350: Breast Cancer Treatment Considerations for Nurses  Episode 348: Breast Cancer Diagnostic Considerations for Nurses  Episode 345: Breast Cancer Screening, Detection, and Disparities  ONS Voice articles: Breast Cancer Prevention, Screening, Diagnosis, Treatment, Side Effect, and Survivorship Considerations  Improve Management of Common Symptoms for Breast Cancer Survivors  Nursing Considerations for Breast Cancer Survivorship Care  Sexual Considerations for Patients With Cancer ONS books:  Breast Care Certification Review (second edition)  Guide to Breast Care for Oncology Nurses  ONS course: Breast Cancer Bundle  ONS Learning Libraries:  Breast Cancer  Genomics and Precision Oncology  Nurse Navigation  Oral Anticancer Medication   Survivorship  ONS Guidelines™ and Symptom Interventions:  Anxiety  Cognitive Impairment  Depression  Fatigue  Clinical Journal of Oncology Nursing article: Survivorship Care: More Than Checking a Box  Clinical Journal of Oncology Nursing supplement: Survivorship Care  American Cancer Society:  Cancer Treatment and Survivorship Facts and Figures  Survivorship: During and After Treatment  Livestrong® Program at the YMCA  National Comprehensive Cancer Network  National Cancer Institute Breast Cancer—Patient Version    To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode  “I think the biggest thing is to really communicate is that people are living with breast cancer for a long, long periods of time, and a lot of that with really good quality overall.” TS 4:07   “As a general rule, they're going to be seen by the breast surgeon probably every four to six months for a while. After about five years, a lot of times people are ready to say, ‘Okay, annually is okay.' And eventually they may let that drop off. But it also depends on did they have a mastectomy? Did they have breast conserving surgery? And then if they had reconstruction with an implant, how often do they see the plastic surgeon? Because they need to check integrity of the implant. So those schedules are really individualized.” TS 13:24  “When you think about long-term effects, I think you need to kind of think about that survivors can have both acute and long-term chronic effects. And a lot of that depends on the specifics of the treatment they had. I think as oncology nurses, we're used to, ‘We give you this chemotherapy or this agent, and these are the side effects.'” TS 15:36  “The diet issues are huge. And I think we are slow to refer to the dietician, you know, you can get them a couple of consults and because you're saying to them, ‘This is really important. We need you to lose weight or we need you to eat more of this.' Ideally, fruits and vegetables are going to be about half of your plate. And what's the difference between a whole grain and not, less processed foods, making sure that they're getting enough protein. And then once again, really kind of making sure that they're not taking a lot of supplements and extra stuff because we don't really understand all that fully and it could be harmful.” TS 34:53  “Breast cancer is a long, long journey, and I think you should never underestimate the real difference that nurses can make. I think they can ask those tough questions. And I think ask the questions that are important to patients that patients may be reluctant to ask. I think giving patients permission to talk about those less-talked-about symptoms and acknowledge that those symptoms are real and that there are some strategies to mitigate those symptoms.” TS 42:28